Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
STAT3 Inhibitor
STAT3-IN-47 is a potent oral inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) pathway. This compound demonstrates significant anti-tumor activity across various cancer cell lines, including HeLa, HepG2, U87, and LN229. By effectively suppressing STAT3 activation in vitro, STAT3-IN-47 serves as a valuable tool for research on solid tumors, with particular relevance to central nervous system malignancies and hepatocellular carcinoma. -
STAT6 Inhibitor
STAT6-IN-8 is a selective inhibitor of the signal transducer and activator of transcription 6 (STAT6), known for its potential anti-inflammatory and anti-allergic properties. This compound serves as a valuable tool for investigating STAT6-associated pathologies, including various inflammatory conditions such as atopic dermatitis and bronchial asthma, as well as allergic diseases like allergic rhinitis and chronic sinusitis. Its applications in research can contribute to a better understanding of these conditions and aid in the development of targeted therapies. -
pSTAT3 Inhibitor
(E/Z)-OSM-SMI-10B is a potent inhibitor of phosphorylated STAT3 (pSTAT3). This compound effectively decreases OSM-induced STAT3 phosphorylation in cancer cells when co-incubated with Oncostatin M (OSM). Its ability to modulate STAT3 signaling makes (E/Z)-OSM-SMI-10B a valuable tool for research in cancer biology and therapeutic development. -
STAT3 Inhibitor
STAT3-IN-23 is a potent inhibitor of signal transducer and activator of transcription 3 (STAT3). By selectively targeting STAT3, this compound disrupts its signaling pathway, leading to decreased tumor cell proliferation and enhanced apoptosis. STAT3-IN-23 is valuable for research applications focused on cancer biology, inflammation, and the understanding of STAT3-mediated signaling in various pathological conditions. -
STAT3 Inhibitor
STAT3-IN-5 is a potent inhibitor of the signal transducer and activator of transcription 3 (STAT3), primarily targeting the phosphorylation of STAT3 at the Y705 residue with an EC50 of 170 nM. This compound effectively blocks cytokine-induced JAK activation and induces apoptosis in cancer cells. STAT3-IN-5 is valuable for research focused on cancer biology and the therapeutic modulation of the STAT3 signaling pathway. -
STAT3 Dual Phosphorylation Inhibitor
STAT3-IN-32 is a potent inhibitor of dual phosphorylation of STAT3, targeting the SH2 domain with a dissociation constant (KD) of 21.3 nM. It effectively inhibits STAT3 phosphorylation at tyrosine 705 and serine 727, leading to the disruption of nuclear transcription and mitochondrial oxidative phosphorylation functions. In cellular assays, STAT3-IN-32 demonstrates an IC50 of 5.3 nM for STAT3 luciferase activity in HEK293T cells and 4.2 nM for ATP production inhibition in BxPC-3 cells. Additionally, STAT3-IN-32 exhibits significant anti-tumor effects in pancreatic cancer xenograft models, making it a valuable compound for cancer research. -
STAT3 Inhibitor
WZ-2-033 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). This compound effectively reduces the proliferation, colony survival, migration, and invasion of cancer cell lines MDA-MB-231, HCC70, and MDA-MB231-4175, with IC50 values of 0.7 μM, 1.3 μM, and 1.3 μM, respectively. Its ability to modulate STAT3 signaling makes WZ-2-033 a valuable tool in cancer research and therapeutic development targeting STAT3-mediated pathways. -
STAT3 Inhibitor
STAT3-IN-43 is a covalent inhibitor that targets the allosteric site at the intersection of the STAT3 coiled-coil domain and DNA-binding domain, demonstrating an IC50 of 40.7 μM. This compound effectively modulates STAT3 activity, making it a valuable tool in cancer research to study the role of STAT3 in tumorigenesis and therapeutic resistance. Its application may extend to elucidating the molecular mechanisms of STAT3-mediated signaling pathways. -
STAT3 Inhibitor
STAT3-IN-4 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway. With dissociation constants (Kd) of 22.75 μM for the mutant STAT3 (I634S/Q635G) and 4.59 μM for the wild-type, this compound demonstrates significant potential in attenuating STAT3 activity. STAT3-IN-4 has been shown to inhibit the proliferation of tumor cells, making it a valuable tool for cancer research and therapeutic studies targeting aberrant STAT3 signaling in various malignancies. -
AK/STAT Signaling Inhibitor
AUH-6-96 is a potent JAK/STAT signaling inhibitor that effectively reduces Unpaired-induced transcriptional activity in Drosophila cells and inhibits tyrosine phosphorylation of STAT92E. It also suppresses both constitutive and IL-6-induced phosphorylation of STAT3 while decreasing levels of tyrosine-phosphorylated JAK3. Furthermore, AUH-6-96 induces apoptosis in cancer cells by downregulating anti-apoptotic genes downstream of STAT3, selectively reducing the viability of cancer cells with dysregulated JAK/STAT signaling. This compound is relevant for research pertaining to Hodgkin's lymphoma, breast cancer, and prostate cancer. -
STAT3 Inhibitor
STAT3-IN-33 is a selective STAT3 inhibitor that demonstrates significant anti-cancer properties. It effectively inhibits cell proliferation in HCT116, MCF-7, and MDA-MB-231 cancer cell lines, with IC50 values of 6.44, 3.29, and 4.86 μM, respectively. This compound is valuable for research focused on the therapeutic applications of STAT3 inhibition in breast and colon cancer. -
STAT3 Inhibitor
STAT3-IN-30 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) with an EC50 of 13.8 μM. This compound effectively impairs STAT3-mediated signaling pathways, thereby influencing cell proliferation and survival. STAT3-IN-30 is suitable for research applications focused on cancer biology, immune response, and chronic inflammatory disorders, providing valuable insights into therapeutic targets involving STAT3 dysregulation. -
STAT3 Inhibitor
inS3-54-A26 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) pathway. It exhibits cytotoxicity in non-cancerous lung fibroblasts with an IC50 of 4.0 μM. This compound is valuable for research applications in cancer biology and therapeutic development, particularly for exploring STAT3's role in oncogenesis and its potential as a target for anti-cancer strategies. -
STAT3 Inhibitor
STAT3-IN-15 is a selective inhibitor of STAT3, a transcription factor implicated in various pathological conditions, including idiopathic pulmonary fibrosis (IPF). This compound effectively inhibits STAT3 phosphorylation, leading to a reduction in migration and deformation of epithelial cells stimulated by TGF-β1. Additionally, STAT3-IN-15 demonstrates the ability to hinder epithelial-mesenchymal transition (EMT), making it a valuable tool for research in fibrosis and related cellular processes. -
STAT3 Inhibitor
Pulchinenoside E2 is a triterpene saponin that functions as a STAT3 inhibitor. It exhibits dual activity by inhibiting STAT3 and autophagy, demonstrating cytotoxic effects on HL-60 cells with an IC50 value of 2.6 µg/mL. This compound is valuable for research applications focused on cancer biology and the modulation of signaling pathways involved in cell proliferation and survival. -
STAT Phosphorylation Inhibitor
XZH-5 is a STAT phosphorylation inhibitor that specifically targets the phosphorylation of STAT3. This compound induces apoptosis in various cancer cell lines and significantly reduces their colony-forming ability. It serves as a valuable tool for researchers investigating the role of STAT3 in tumorigenesis and potential therapeutic strategies for cancer treatment. -
STAT3 Inhibitor
PMMB-187 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3), showing an IC50 value of 1.81 μM in MDA-MB-231 breast cancer cells. This compound effectively induces apoptosis by disrupting STAT3's transcriptional activity and nuclear localization, leading to a decrease in downstream gene expression. Additionally, PMMB-187 diminishes mitochondrial membrane potential, increases reactive oxygen species (ROS) production, and upregulates apoptosis-related protein levels. Its unique mechanism positions PMMB-187 as a valuable tool in cancer research applications. -
IRS1/2/STAT3 Inhibitor
NT219 is a potent dual inhibitor of insulin receptor substrates 1 and 2 (IRS1/2) and signal transducer and activator of transcription 3 (STAT3). It disrupts IRS1/2 degradation and inhibits STAT3 phosphorylation, impacting essential signaling pathways associated with various oncogenic processes. NT219 is relevant for research applications focused on cancer biology, particularly in understanding the interplay of these critical signaling molecules in tumor progression and resistance. -
STAT3 Inhibitor
STAT3-IN-9 is a selective inhibitor of STAT3, specifically targeting its activation by preventing Tyr705 phosphorylation while leaving STAT1 (Tyr701) unphosphorylated. This compound demonstrates significant biological activity by inducing apoptosis and causing cell cycle arrest at the G2/M phase. It can be effectively utilized in research applications focusing on cancer biology and the role of STAT3 in tumor progression. -
STAT3 Inhibitor
STAT3-IN-53 is a selective inhibitor of STAT3, targeting its SH2 domain with a Kd value of 6.16 μM. This compound effectively suppresses phosphorylation at the Y705 site, thereby inhibiting the IL-6/JAK/STAT3 signaling pathway. By downregulating the transcription and expression of critical oncogenes such as cyclin D1 and c-Myc, STAT3-IN-53 induces cell cycle arrest and promotes apoptosis, demonstrating potential anticancer activity, particularly in colorectal cancer research applications. -
STAT3 Inhibitor
STAT3-IN-18 is a STAT3 inhibitor that selectively targets the JAK2-STAT3 signaling pathway, demonstrating significant anti-proliferative effects in breast cancer cells. This compound promotes apoptotic cell death through the activation of caspase-3 and increases cleaved polyADP-ribose polymerase levels. Additionally, STAT3-IN-18 enhances the maturation and antigen presentation of dendritic cells, while exhibiting favorable safety profiles in vivo, making it a valuable tool for cancer research and immunotherapy studies. -
Miticide/STAT3 Inhibitor
Fluacrypyrim is a potent miticide that functions as a selective inhibitor of the STAT3 signaling pathway. It effectively induces growth arrest and apoptosis in STAT3-dependent cancer cells by significantly decreasing cyclin D1 protein and mRNA levels, leading to G1 cell cycle arrest. Additionally, Fluacrypyrim mitigates irradiation-induced hematopoietic system injury by protecting hematopoietic stem cells from apoptosis. Its analgesic and anti-inflammatory properties are demonstrated through the inhibition of uterine smooth muscle contraction and inflammatory responses, making it a valuable reagent for cancer and inflammation research. -
STAT3 Inhibitor
STAT3-IN-10 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3), exhibiting an IC50 value of 5.18 µM. This compound directly interacts with the SH2 domain of STAT3, leading to the induction of apoptosis in cancer cells. STAT3-IN-10 is ideal for research applications focused on elucidating STAT3 signaling pathways and exploring therapeutic strategies for cancer treatment. -
STAT3 Inhibitor
STAT3-IN-50 is a potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) with an IC50 of 0.259 μM. This compound induces apoptosis and effectively inhibits the proliferation of colon and liver cancer cells. It is a valuable tool for research focused on the mechanisms of colon and liver cancers. -
STAT3 Inhibitor
HJC0152 (free base) is a potent and orally active inhibitor of STAT3. It effectively disrupts cell cycle progression and promotes apoptosis, making it a valuable tool for cancer research. Notably, HJC0152 (free base) demonstrates significant suppression of MDA-MB-231 xenograft tumor growth in murine models, indicating its potential utility in studying STAT3-related pathways in cancer. -
STAT5 Inhibitor
BP-1-108 is a selective inhibitor of STAT5, exhibiting a Ki value of 8.3 μM. This compound demonstrates significant anticancer activity by inducing apoptosis in leukemia cells through the inhibition of STAT5 phosphorylation. BP-1-108 is valuable for research applications focusing on acute myeloid leukemia and prostate cancer. -
JAK2/STAT3 Inhibitor
DPP is a Platinum(IV) complex featuring a pterostilbene-derived axial ligand that specifically targets the JAK2/STAT3 signaling pathway. This compound displays significant antiproliferative activity against breast cancer cells by inducing apoptosis through the activation of caspase-3 and cleavage of poly ADP-ribose polymerase. Additionally, DPP enhances the maturation and antigen presentation capability of dendritic cells, demonstrating favorable safety profiles in in vivo studies, making it a promising candidate for cancer immunotherapy research. -
STAT3 Inhibitor
HJC0416 is a potent inhibitor of STAT3, exhibiting significant antiproliferative activity and the ability to induce apoptosis. This compound effectively reduces the expression of phosphorylated STAT3 (Tyr-705) and Cyclin D1 while increasing the levels of cleaved caspase-3. HJC0416 demonstrates promising anti-tumor effects, making it relevant for cancer research applications focused on targeting the STAT3 signaling pathway. -
STAT3 Inhibitor
7-epi-Isogarcinol is a STAT3 inhibitor that exhibits moderate antiproliferative activity. By blocking the STAT3 signaling pathway, it effectively induces apoptosis and inhibits cell migration. This compound is valuable for research applications focused on cancer biology and the exploration of therapeutic strategies targeting STAT3-mediated pathways. -
JAK2/STAT3 Inhibitor
Cernuumolide J is a selective inhibitor of JAK2/STAT3 signaling pathway. It induces G2/M phase arrest and apoptosis in HEL leukemia cells by downregulating the phosphorylation of JAK2, STAT3, and Erk, while promoting the phosphorylation of JNK and p38 MAPK. Cernuumolide J exhibits a concentration-dependent growth inhibition of HEL leukemia cells, with an IC50 value of 1.79 μM, making it a valuable compound for research in anti-cancer therapy. -
STAT3 Inhibitor
STAT3-IN-52 is a selective inhibitor of signal transducer and activator of transcription 3 (STAT3) that acts by binding to the phosphorylated tyrosine 705 (pY705) site, with a Ki value of 440 nM. This compound effectively blocks the phosphorylation and dimerization of STAT3, leading to cytotoxic effects in various cancer cell lines, including MDA-MB-231 breast cancer cells (IC50 = 0.7 μM), UW426 medulloblastoma, and BKPC3 pancreatic cancer cells. Additionally, STAT3-IN-52 induces apoptosis, inhibits STAT3 nuclear transport and DNA binding, and downregulates the expression of the STAT3 target gene MMP9, making it a valuable reagent for studying STAT3 dysregulation in cancer research. -
IL6/STAT3 Inhibitor
Angoline is a selective inhibitor of the IL6/STAT3 signaling pathway, demonstrating an IC50 of 11.56 μM. It effectively inhibits the phosphorylation of STAT3, leading to reduced expression of target genes associated with cancer progression. This compound is valuable for research applications focused on cancer biology and the modulation of inflammatory responses. -
TYK2 Inhibitor
QL-1200186 is a selective, orally active allosteric inhibitor specifically targeting the pseudokinase domain JH2 of tyrosine kinase TYK2, exhibiting an IC50 of 0.06 nM with 164-fold selectivity over TYK1 JH2 (IC50 = 9.85 nM). By stabilizing the TYK2 JH2 conformation, QL-1200186 inhibits the activity of the JH1 catalytic domain and disrupts the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. This compound effectively reduces the production of Th1/Th17-related cytokines and has shown promise in alleviating skin inflammation in Imiquimod-induced psoriasis models, making it relevant for the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE). -
cytochrome oxidase inhibitor
Artesunate is a semisynthetic derivative of artemisinin used to treat malaria. It has also been shown to effective against other parasites such as liver flukes. Artesunate also demonstrates cytotoxic action against cancer cell lines of different tumor types. Artesunate has been shown to inhibit TNF--induced production of proinflammatory cytokines via inhibition of NF-B and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. -
Stat3 inhibitor
Cryptotanshinone, a natural compound isolated from the roots of Salvia miltiorrhiza Bunge (Danshen), dramatically blocks STAT3 Tyr705 phosphorylation but not STAT3 Ser727 phosphorylation in DU145 cells, and significantly inhibits JAK2 phosphorylation with IC50 of ~5 μM without affecting the phosphorylation of upstream kinases c-Src and EGFR. -
AK-STAT3 signaling pathway inhibitor
Ganoderic acid A can inhibit of the JAK-STAT3 signaling pathway, also inhibit proliferation, viability, ROS. -
Pdia3/ERp57 activator, STAT3 inhibitor
Diosgenin palmitate, also known as Diosgenin hexadecanoate, is the hexadecanoic ester of Diosgenin. Diosgenin, a phytosteroid sapogenin, is the product of hydrolysis by acids, strong bases, or enzymes of saponins, extracted from the tubers of Dioscorea wild yam, such as the Kokoro. -
STAT3/NF-κB Inhibitor
Triacetylresveratrol is an acetylated analog of Resveratrol that functions as an inhibitor of STAT3 and NF-κB signaling pathways. It effectively reduces the phosphorylation levels of STAT3 and NF-κB in a dose- and time-dependent manner in PANC-1 and BxPC-3 cancer cell lines. Its promising anticancer activity makes it a valuable tool for research in cancer biology and therapeutic development. -
PTPN1/PTPN2 Inhibitor
Osunprotafib (ABBV-CLS-484) is an orally active and selective active site PTPN1 (IC50: 2.5 nM) and PTPN2(IC50: 1.8 nM) inhibitor. Osunprotafib has 6-8-fold weaker activity on PTPN9 and no detectable activity on SHP-1 or SHP-2. Osunprotafib increases the sensitivity of human cancer cell lines to IFNγ. Osunprotafib generates robust anti-tumor immunity by enhancing JAK-STAT signalling and reducing T cell dysfunction. -
STAT3 Inhibitor
Pentadecanoic acid is a saturated fatty acid that serves as an inhibitor of STAT3, a critical transcription factor involved in cellular signaling pathways. Its primary biological activity includes modulation of inflammatory responses and potential anti-cancer effects. This compound is utilized in research applications focused on cancer therapy, inflammation studies, and metabolic regulation. -
STAT3 Inhibitor
STAT3-IN-13 is a potent inhibitor of the STAT3 signaling pathway, specifically targeting the SH2 domain with a binding affinity of 0.46 μM. This compound effectively inhibits the phosphorylation of STAT3 at Y705, subsequently reducing the expression of downstream target genes. In vitro studies demonstrate its ability to induce apoptosis, while in vivo applications show suppression of tumor growth and metastasis. STAT3-IN-13 is a valuable tool for cancer research, particularly in studies focused on the modulation of aberrant STAT3 activity. -
STAT3 Inhibitor
Atiprimod hydrochloride is a potent inhibitor of the signal transducer and activator of transcription 3 (STAT3). It demonstrates significant antitumor, anti-inflammatory, and anti-angiogenic properties by blocking IL-6 and VEGF signaling pathways, inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod effectively induces cell cycle arrest, autophagy, and apoptosis in various cancer cell types, particularly through the activation of the PERK/eIF2α/ATF4/CHOP pathway in breast cancer cells. Its efficacy in tumor xenograft mouse models underscores its potential for investigating therapeutic approaches in conditions such as pituitary adenoma, breast cancer, multiple myeloma, and acute myeloid leukemia (AML). -
STAT3 Inhibitor
Atiprimod dimaleate is a selective inhibitor of the transcription factor STAT3, demonstrating significant antitumor, anti-inflammatory, and anti-angiogenic properties. By disrupting IL-6 and VEGF signaling pathways, it inhibits the phosphorylation of JAK2 and JAK3, effectively blocking the JAK-STAT signaling cascade. Atiprimod dimaleate induces cell cycle arrest, promotes autophagy and apoptosis, and activates the PERK/eIF2α/ATF4/CHOP pathway to trigger ER stress-mediated apoptosis in cancer cells. This reagent is valuable for research related to breast cancer, pituitary adenoma, multiple myeloma, and acute myeloid leukemia (AML), and has shown promising anti-tumor activity in xenograft mouse models. -
STAT3 Inhibitor
LY5 is a potent inhibitor of STAT3, exhibiting an IC50 of 0.5 μM. It induces apoptosis and effectively inhibits STAT3 phosphorylation, demonstrating significant antitumor activity in vivo. This compound is utilized in cancer research to explore the mechanisms of STAT3-related signaling pathways and their implications in tumorigenesis. -
STAT3 Inhibitor
HJC0123 is a potent STAT3 inhibitor that effectively suppresses the proliferation of hepatic stellate cells while inducing cell cycle arrest and apoptosis. It reduces STAT3 phosphorylation, nuclear translocation, and transcriptional activity, leading to increased IL-6 production and inhibition of Smad2/3 phosphorylation, along with down-regulation of SOCS3. HJC0123 serves as a valuable tool for investigating liver fibrosis and related pathways. -
STAT3 Inhibitor
STAT3-IN-38 is a selective inhibitor of the signal transducer and activator of transcription 3 (STAT3) protein, exhibiting a KD value of 45.33 µM. By binding to the SH2 domain of STAT3, it effectively inhibits phosphorylation at the pTyr705 site, leading to the downregulation of downstream genes such as Survivin and Mcl-1. This compound has demonstrated the ability to block cell-cycle progression and induce apoptosis in colorectal cancer cells, making it a valuable tool for cancer research and therapeutic development. -
IKK/STAT3 Dual Inhibitor
ACHP is a selective IκB kinase (IKK) and STAT3 dual inhibitor, demonstrating potent inhibitory activity with IC50 values of 8.5 nM and 250 nM for IKKβ and IKKα, respectively. It effectively disrupts the STAT3 signaling pathway, leading to cancer cell cycle arrest and apoptosis. Additionally, ACHP exhibits significant anti-inflammatory properties in preclinical models, such as the mouse ear edema model. This compound is a valuable tool for research in anti-inflammatory and anti-cancer studies, including applications in multiple myeloma and leukemia. -
HDAC3/p-STAT3 Inhibitor
1-Stearoyl-sn-glycero-3-phosphocholine is an inhibitor of histone deacetylase 3 (HDAC3) and the phosphorylation of signal transducer and activator of transcription 3 (p-STAT3). This compound has demonstrated the ability to induce apoptosis and exhibits significant anticancer activity in chronic myelogenous leukemia (CML) K562 cells. It serves as a valuable tool for researchers investigating the therapeutic potential of HDAC inhibitors in cancer treatment.
